BRCA1 and ovarian carcinoma: With the advancement of precision medicine and targeted therapy, detection of BRCA1/2 mutations in blood and/or tumor tissues of patients with breast and ovarian cancer will help select targeted drugs and chemotherapy regimens and better assess prognosis (Robson et al., 2017).